Despite being originally endemic among populations from Southern Europe, Africa, the Middle East and Asia, haemoglobinopathies are occurring widely across the world. Today, haemoglobin disorders can be effectively prevented, treated and managed, but experts believe that a tailored, comprehensive, holistic approach to haemoglobinopathies is not equally applied across the EU member.
This is one of the conclusions of the report "Haemoglobinopathies on the Move: Is Europe ready?", developed by a group of experts from ENERCA and the Thalassemia International Federation (TIF), in collaboration with the International Organization for Migration (IOM), Migration Health Division, Regional Office Brussels. Novartis Farma S.p.A. sponsored this project through in-kind support services from Burson-Marsteller Brussels. ENERCA encourages a careful reading of the document and its conclusions to understand the situation of haemoglobinopathies in Europe, and work towards a better management of these diseases.
The European Union has made remarkable progress in the area of rare diseases, but there is still much pending work. The present document analyses the situation country by country, presenting a specific fact sheet for each European country. The documents ends with a comprehensive list of key findings and conclusions around:
DOWNLOAD the full report.